Final Program

398 WEDNESDAY • MAY 18
D88
BEHAVIORAL • CLINICAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
THE PATIENT-CENTERED JUGGERNAUT: THE
RIGHT MOVE FOR CLINICAL CARE, POLICY, AND
RESEARCH?
Assemblies on Behavioral Science and Health Services Research;
Critical Care; Thoracic Oncology
1:30 p.m. - 3:30 p.m. MOSCONE CENTER
Room 303/305 (South Building, Esplanade Level)
Target Audience
Clinicians or researchers who incorporate patient centered outcomes in their
practice or research.
Objectives
At the conclusion of this session, the participant will be able to:
• understand the benefits and limitations of patient and family satisfaction as
a quality metric in critical care;
• learn about advantages and disadvantages of shared decision making as a
policy requirement in lung cancer screening;
• determine if the methods to conduct high quality patient engaged research
are available for implementation by researchers.
There is an emerging trend toward incorporating patients' values, opinions and
feedback in both patient care and research. Patient engagement is expected to
address patients’ health care concerns and close the gaps in evidence needed
to improve key outcomes. However, it remains unclear how this process will
actually improve meaningful clinical outcomes and research products. Despite
the difficulties in measuring the benefits and harms of this strategy, patient
centered approaches are being adopted in clinical care, health policy and
research. We will select case examples from key pillars of PCCM to highlight
the current controversies for and against incorporating patient centered
outcomes.
Chairing: D.R. Sullivan, MD, MA, Portland, OR
L.C. Feemster, MD, MSc, Seattle, WA
R.S. Wiener, MD, MPH, Boston, MA
1:30 A Patient’s Perspective
J. Lefferts, San Francisco, CA
1:35 Incorporating Patient Centered Outcomes in Clinical Practice
and Research
S.D. Halpern, MD, PhD, Philadelphia, PA
1:47 PRO: Patient and Family Satisfaction is a Key Quality Metric in
Critical Care
E.K. Kross, MD, Seattle, WA
2:02 CON: Patient and Family Satisfaction is a Key Quality Metric in
Critical Care
G.D. Rubenfeld, MD, MSc, Toronto, Canada
2:17 General Discussion
2:21 CON: Shared Decision Making Improves Outcomes in Lung
Cancer Screening
C.G. Slatore, MD, Portland, OR
2:36 PRO: Shared Decision Making Improves Outcomes in Lung
Cancer Screening
R.S. Wiener, MD, MPH, Boston, MA
2:51 General Discussion
2:55 PRO: We Possess the Methods to Conduct High Quality
Patient Engaged Research
S. Parthasarathy, MD, Tucson, AZ
3:10 CON: We Possess the Methods to Conduct High Quality
Patient Engaged Research
M. Helfand, MD, MS, MPH, Portland, OR
3:25 General Discussion
D89
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
NOVEL APPROACHES TO TREAT PULMONARY
INFECTIONS
Assemblies on Allergy, Immunology and Inflammation; Microbiology,
Tuberculosis and Pulmonary Infections; Pediatrics; Respiratory Cell and
Molecular Biology; Respiratory Structure and Function
1:30 p.m. - 3:30 p.m. MOSCONE CENTER
Room 3007/3009 (West Building, Level 3)
Target Audience
Scientists, physician scientists and clinicians working on developing and
utilizing novel therapeutics to treat and prevent pulmonary infections.
Objectives
At the conclusion of this session, the participant will be able to:
• identify novel strategies for treatment of respiratory infection.
• understand how these novel therapies target the pathogen or the host to
promote innate immune clearance.
• recognize and understand the pitfalls and/or challenges present in the
development of such therapies.
Opportunistic bacterial pathogens are a common cause of respiratory infection,
especially in the immune compromised or in hospital settings. Widespread use
of broad spectrum antibiotics has led to the emergence of antibiotic resistance
in a group of respiratory pathogens labeled the ESKAPE pathogens
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species)
and damaging effects of antibiotics on the gut microbiome. These factors,
coupled with a reduction in the discovery rate of new antimicrobial therapies,
necessitate efforts aimed at identifying novel and potentially pathogen specific
antimicrobial therapeutics. This session will highlight recent discovery of novel
treatment modalities for respiratory infection and exacerbation, including
strategies targeting both the microbe and the host.
Chairing: J.K. Kolls, MD, Pittsburgh, PA
T. Cohen, PhD, Gaithersburg, MD
1:30 Antibodies: A Pathogen Specific Approach to Combating
Respiratory Infection
S. Projan, PhD, Gaithersburg, MD
ATS 2016 • San Francisco